索拉非尼
肝细胞癌
医学
生活质量(医疗保健)
内科学
肿瘤科
癌
护理部
作者
Richard S. Finn,Masatoshi Kudo,Gisoo Barnes,Tim Meyer,Frédéric Boisserie,Ramil Abdrashitov,Yaxi Chen,Songzi Li,Andrew X. Zhu,Shukui Qin,Arndt Vogel
出处
期刊:Liver cancer
[Karger Publishers]
日期:2024-02-21
卷期号:13 (5): 548-560
摘要
RATIONALE-301 (NCT03412773) was a global, phase 3 study comparing the efficacy and safety of tislelizumab with sorafenib as first-line (1L) treatment in adult patients with unresectable hepatocellular carcinoma (HCC) that met its primary endpoint of noninferiority in overall survival (OS). This analysis compared health-related quality-of-life (HRQOL) outcomes between the arms.
科研通智能强力驱动
Strongly Powered by AbleSci AI